Heat Biologics (HTBX) Receiving Somewhat Favorable Press Coverage, Report Finds

Media headlines about Heat Biologics (NASDAQ:HTBX) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Heat Biologics earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.4638288051677 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

Heat Biologics (NASDAQ HTBX) traded down $0.09 during midday trading on Friday, reaching $3.23. The company had a trading volume of 346,588 shares, compared to its average volume of 464,830. The firm has a market capitalization of $13.94, a P/E ratio of -0.83 and a beta of 0.56. Heat Biologics has a 1-year low of $2.60 and a 1-year high of $12.50.

Heat Biologics (NASDAQ:HTBX) last posted its quarterly earnings data on Monday, November 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.30. The business had revenue of $0.47 million during the quarter, compared to the consensus estimate of $0.50 million. Heat Biologics had a negative return on equity of 149.69% and a negative net margin of 1,184.92%. research analysts forecast that Heat Biologics will post -25.3 EPS for the current year.

Separately, ValuEngine downgraded Heat Biologics from a “sell” rating to a “strong sell” rating in a report on Friday.

TRADEMARK VIOLATION NOTICE: “Heat Biologics (HTBX) Receiving Somewhat Favorable Press Coverage, Report Finds” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://sportsperspectives.com/2018/02/03/heat-biologics-htbx-receiving-somewhat-favorable-press-coverage-report-finds.html.

Heat Biologics Company Profile

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Insider Buying and Selling by Quarter for Heat Biologics (NASDAQ:HTBX)

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply